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Abstract
Background: Fibromyalgia (FM) is a complex syndrome that affects many aspects of the patients life and it is very
difficult to evaluate in clinical practice. A recent study has developed the Combined Index of Severity of
Fibromyalgia (ICAF), an instrument that evaluates diverse aspects of FM and offers five indices: emotional, physical,
active coping, passive coping and total. The objective of this study is to confirm the structure of the ICAF, check its
test-retest reliability, assess its sensitivity to change, and compare the results obtained in a sample of patients with
fibromyalgia with another sample of healthy controls.
Methods: A total of 232 patients took part in the study, 228 women and 4 men, with a mean age of 47.73 years
of age (SD = 8.61) and a time of disease evolution since diagnosis of 4.28 years (SD = 4.03). The patients from the
FM group completed the ICAF. Between one and two weeks later, they again attended the clinic and complete
the 59 items on the ICAF (retest) and immediately afterwards they began treatment (according to daily clinical
practice criteria). A sample of healthy subjects was also studied as a control group: 110 people were included (106
women and 4 men) with a mean age of 46.01 years of age (SD = 9.35). The study was conducted in Spain.
Results: The results obtained suggest that the four-factor model obtained in the previous study adequately fits the
data obtained in this study. The test-retest reliability and internal consistency were all significant and show a high
degree of correlation for all the factors as well as in overall score. With the exception of the passive coping factor,
all the other scores, including the overall score, were sensitive to change after the therapeutic intervention. The
ICAF scores of the patients with fibromyalgia compared with those of the control group were markedly different.
Conclusions: The findings suggest that the ICAF is a valid, reliable, sensitive to change instrument with the added
advantage that it offers some additional domains (factors) that provide very valuable information regarding the
most delicate aspects of the patient, which must be addressed at the time of treatment in daily clinical practice.
Background
Fibromyalgia syndrome is a complex syndrome that
affects many aspects of the patients life and it is very
difficult to evaluate in clinical practice. In addition to
the ACR classification criteria [1], which is also the sub-
ject of debate [2], it has been defined as the existence of
a group of symptoms that includes pain, fatigue, sleep
disturbance, morning stiffness, cognitive dysfunction,
loss of functional capacity, and emotional aspects such
as anxiety, changes in mood or in the way in which the
patients face the disease [3].
The mere demarcation of the symptoms indicated has
been the object of debate, as have the tools used to evalu-
ate them, due to the enormous quantity of existing instru-
ments [4]. Nonetheless, the symptoms listed have been
recognised as relevant when assessing the syndrome; it
empirically necessary to establish their relative importance
or even determine combined indices that take into
account the influence of the symptoms and allow compre-
hensive indices of the disorder to be obtained [3].
The current efforts being undertaken through Out-
come Measures in Rheumatoid Arthritis Clinical Trials
(OMERACT) [3] pursue the objective of finding a core
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data set to evaluate patients with FM in clinical trials.
One of the difficulties OMERACT has run up against is
due to the fact that some of the symptoms that most
concern the patient, such as morning stiffness [5], do
not completely concur with those established by OMER-
ACT, and therefore have had to be incorporated to the
core data set because they were not initially well-
assessed by the investigators.
Furthermore, some of the FM symptoms and domains
do not possess good tools that can measure sensitivity
to change. Such is the case of quality of life, in which
the questionnaires that have been used do not have a
good discriminating power [4]. However, a tool is
needed in daily clinical practice that allows for a fast,
overall evaluation of patients, with an aim to assess the
severity of their disease and the most relevant aspects to
be dealt with in their treatment. In light of this need,
Vallejo et al. [6] has recently developed the Combined
Index of Severity of Fibromyalgia (ICAF), an instrument
that evaluates the aforementioned symptom areas and
offers five indices: emotional, physical, active coping,
passive coping and total. The emotional factor stresses
the role of emotional aspects such as anxiety and
depression; the physical factor evaluates pain, fatigue,
sleep quality and functional capacity; the active coping
includes positive coping strategies, and passive coping
identifies a group of particularly severe affected patients.
Global score integrates the four previous factors. This
instrument was created by using several other question-
naires that are well-known for their scientific integrity,
and the results obtained have allowed for patients to be
differentiated based on external criteria, such as medical
history, physical functioning tests, occupational situa-
tion, etc. In order to understand this research it is highly
recommended to read the paper where the ICAF devel-
opment and instruments used for its validation are
described [6].
The objective of this study is to confirm the structure
of the ICAF, check its test-retest reliability, assess its
sensitivity to change, and compare the results obtained
in a sample of patients with fibromyalgia with another
sample of healthy controls.
Methods
Study design
A longitudinal, open, prospective, comparative, 3-visit
study was designed. During the first visit, at baseline,
patient demographics and clinical characteristics were
collected, and scales included in the study were adminis-
tered for the first time. After patients completed the eva-
luation at the second visit (retest), they were prescribed
the treatment considered to be most appropriate by the
rheumatologist, which consisted of information on any
aspects of the disease and individualised prescription of
physical exercise and medication, all according to usual
daily clinical practice. This treatment did not include any
specific psychological treatment or emotional support. A
final visit was carried out at 3 months in which the ICAF
was applied again. Between these two visits, another
optional visit was recommended to adjust the treatment
or reinforce compliance, according to individual patient
needs. However, at this intermediate visit, no information
was recorded and it could be replaced by a telephone
call, at the investigator’s discretion. The questionnaires
used to draft the ICAF were selected from among those
commonly used to evaluate the most relevant symptoms
of fibromyalgia. The following questionnaires were used:
the Fibromyalgia Impact Questionnaire [7-9], the Hospi-
tal Anxiety and Depression Scale [10-12], the Brief Pain
Inventory [13,14], the Fatigue Assessment Scale [15], the
Health Assessment Questionnaire [16,17], the General
Health Questionnaire (GHQ-28) [18,19], the Chronic
Pain Coping Inventory [20], the Arthritis Self-efficacy
Scale [21], and a Sleep Quality Scale where 0 = very good
and 10 = very poor. All methods for developing the ICAF
have been previously described [6]. The ICAF question-
naire and the scoring system can be found in the Addi-
tional File 1.
Patients, control group and study procedures
A total of 232 patients took part in the study, 228
women and 4 men, with a mean age of 47.73 years of
age (SD = 8.61) and a time of disease evolution since
diagnosis of 4.28 years (SD = 4.03).
Patient selection was performed by following the same
criteria as for the study conducted for the development
of the ICAF [6]. The study population was primarily
urban and comprised women and men over 18 years of
age with a diagnosis of fibromyalgia according to ACR
classification criteria [1], recruited consecutively from 15
rheumatology clinics throughout the country. Exclusion
criteria included: patients presenting other concomitant
diseases with severely impaired physical or functional
capacity, rheumatic inflammatory diseases, cardiovascu-
lar or pulmonary diseases with poor aerobic capacity,
uncontrolled psychiatric diseases, patients involved in
litigation processes, and patients included in any other
clinical trial.
The patients from the FM group followed the process
described below. Once accepted for the study and hav-
ing signed the informed consent form, they completed
the ICAF [6]. Between one and two weeks later, they
again attended the clinic to exclusively complete the
ICAF (retest) and immediately afterwards they began
treatment. The treatments were established according to
usual clinical practice criteria, following the recommen-
dations of the SER (Spanish Society of Rheumatology)
consensus document [22]. The last visit was performed
Vallejo et al. Health and Quality of Life Outcomes 2011, 9:39
http://www.hqlo.com/content/9/1/39
Page 2 of 7
three months after having started treatment and at this
point the patients completed the ICAF again.
A sample of healthy subjects was also studied as a
control group. The control group subjects were selected
among healthcare personnel and among the companions
of those patients who attended the clinic for reasons
other than FM, chronic lumbar pain, or other causes of
chronic pain. To select the control group, the same
exclusion criteria that were used for the FM patient
group were used, with the additional criteria that the
subjects could not have any chronic disease, clinical
symptoms compatible with FM or any type of musculos-
keletal pain of any aetiology. When the subjects were
accepted, they signed the informed consent form to par-
ticipate in the study.
The subjects in the control group only filled in the
ICAF at the first visit. In this control group, 110 people
were included (106 women and 4 men) with a mean age
of 46.01 years of age (SD = 9.35). There were no signifi-
cant differences in terms of age and sex as compared to
the FM patient group.
The study protocol was approved by the Independent
Ethics Committee of Hospital Universitario Gregorio
Marañón (Madrid, Spain). The study was conducted in
Spain.
Statistical analysis
The SPSS statistical package version 17.0 was used
throughout.
Confirmatory factor analysis was performed for the
results obtained from giving the ICAF and the structure
of the questionnaire was put to the test to see whether
it fit that obtained previously by Vallejo et al. [6]. To
this end, the 4-factor model obtained by said study
(emotional, physical, active coping and passive coping)
was applied and the AMOS 17 programme was used
(AMOS 17 is a component of the SPSS 17.0 statistical
package).
The indices of the fit of the model to the data allow
for the assessment of whether said model fits the data,
keeping in mind the nature of the sample and its var-
iance. In structural equation modelling, there is not a
single index or a single set of indices to evaluate the fit
of the model. Normally, several indices are calculated
that contribute as a group to determining the degree to
which the model fits the data [23]. Along these lines, we
decided to use the following indices: the relative chi-
square (CMIN/DF), the goodness-of-fit index (GFI),
Bentler’s comparative fit index (CFI) [24], the Tucker-
Lewis Index (TLI) [25], and the root mean square error
of approximation (RMSEA), following the guidelines by
Jackson et al. [26].
The most used and simplest index is the relative chi-
square (CMIN/DF). Values below 1 suggest a perfect fit,
higher values around 2 or 3 suggest an adequate fit and
values close to 5 suggest an inadequate fit [27]. This
index is very sensitive to sample size, and therefore
other indices must be considered. The GFI behaves in a
similar manner as R2 in regression analysis. The CFI
varies from 0 to 1. The closer the CFI and GFI values
are to 1 [28,29], the better the fit of the model. Values
over 0.9 suggest a good fit to the model. The same
occurs with the TLI [23]. The RMSEA must have values
below 0.8, and the fit is considered to be very good
when the values are below 0.5 [30].
The scores obtained in the ICAF were transformed
into T scores, as in the previous study [6]. The mean
and standard deviation for each scale was taken from
that cited in the study mentioned and they can be con-
sulted in the Additional File 1.
To study the test-retest reliability, Spearman’s intra-class
correlation coefficient (ICC) was determined between the
baseline ICAF scores and those obtained later, with an
interval of 1-2 weeks. Internal consistency was determined
by calculating the Cronbach’s alpha coefficient.
To make comparisons between the ICAF scores
obtained before and after the therapeutic intervention, a
comparison of means was performed using the t-test for
related samples. To evaluate the clinical relevant change,
standardized response mean (SRM) and the standard
error of measurement (SEM) were calculated to deter-
mine the change scores when 1 SRM is considered.
Finally, the values obtained in the different ICAF




The results obtained suggest that the four-factor model
obtained in the previous study [6] (Vallejo et al., 2010)
adequately fits the data obtained in this study: [X2 (113)
= 211.87; CMIN/DF = 1.87; CFI = .91; GFI = .92; TLI =
.90; RMSEA = .05]. X2 was statistically significant (p <
.001), which suggests that there is a part of the variance
that is not explained by the model.
Test-retest reliability and internal consistency
The ICAF was given to the patients at two different
times during the study with an interval of between one
to two weeks. The coefficients of correlation obtained
between the two sessions can be seen in Table 1. The
values of the coefficients were all significant with a
value of p < 0.01 and show a high degree of correlation
for all the factors as well as in overall score.
The internal consistency of each one of the factors
according to the Cronbach’s alpha coefficient and the
ICC can also be seen in Table 1. All the factors show a
high degree of internal consistency.
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Sensitivity to change
The comparison between the ICAF scores before and
after starting treatment can be observed in Table 2. With
the exception of the passive coping factor, all the other
scores, including the global score, were sensitive to
change after the therapeutic intervention. The SRM
shows the responsiveness of the measure to the clinical
change. SEM was also calculated to interpret score on
Patient Reported Outcome (PRO). This 1 SEM bench-
mark implies an effect size of 0.20, consistent with
Cohen’s small-to moderate effect. The mean change
score to each component of the ICAF is shown in table 2.
Comparison between the patients and controls
The ICAF scores of the patients with fibromyalgia and
those of the control group are shown in Table 3. A gra-
phic representation of mean scores of fibromyalgia
patients and controls in the ICAF factors are shown in
Figure 1.
Discussion
This study used a new sample of fibromyalgia patients
to confirm the factorial structure of the ICAF obtained
by the previous study [6]. Therefore, it confirms the
results obtained as well as the precise reference values
to calculate the T scores, as reflected in the Additional
File 1. Said Additional File 1 also includes the ICAF, as
well as the correction guidelines, in light of the original
study data.
The study of the scientific integrity of the instrument
was also completed, offering satisfactory data with
regard to its test-retest reliability, the internal consis-
tency of the different factors included in the ICAF, as
well as its sensitivity to change. The total score of the
questionnaire, as well as the scores for the emotional,
physical and active coping factors all varied with statisti-
cal significance after conventional medical treatment.
There was not a statistically significant change in the
passive coping factor. It should be mentioned that in the
previous study [6], the greatest score in the passive cop-
ing factor was characteristic of poorer physical shape,
measured by the 6-minute walk test [31]. Recently, Kars-
dorp and Vlaeyen [32] found that fibromyalgia patients
who refrain from physical activity and seek help (asking
for assistance) to control their pain are characterised by
greater severity and disability. It is possible that the
changes in coping strategies, and particularly the passive
strategies, require longer periods of intervention and eva-
luation. The pain-avoidance factor (passive pain-coping)
is particularly relevant to determine a risk of longer
aggravated distress in fibromyalgia [33]. It is reasonable
that the change score for passive coping is higher
(0.8391) than in the other factors. This implies that the
minimal score change (1 SEM) in this factor should also
be higher than in the others factors and corresponds well
with the level of distress associated with passive coping
[33]. This should be dealt with through therapeutic inter-
vention studies that have a longer duration, using psy-
chological treatment and physical exercise.
The results obtained in passive coping must be con-
sidered in relation with gender. In FM studies female
percentages are about 95% or more [32,33], which indi-
cates that there is an influence of specific gender differ-
ences in pain perception, specifically in coping with
pain. Women report more pain than men [34], and men
use more active coping than women [35]. It is likely
that female FM patients may have more difficulties to
reduce passive coping and to increase active coping.
The ICAF scores in patients and controls show large
differences, both regarding the overall score and each of
Table 1 Test-retest reliability and measurement of the














Table 2 Sensitivity to change: Comparison of measurements before and after intervention in patients with
fibromyalgia
Mean Pre Mean Post Mean Diff. t SRM 1 SEM
Mean change score
Emotional 50.74 47.85 2.89 5.96*** 0.48 0.78
Physical Activity 54.27 49.18 5.09 12.12*** 0.89 0.62
Active Coping 48.96 50.35 -1.39 -2.37* 0.25 0.53
Passive Coping 51.57 52.65 -1.08 -1.56 0.20 0.84
Total 52.55 48.00 4.55 8.44*** 0.66 0.64
N = 22.
*p < .05, ***p < .001 SMR: standardized response mean; SEM: standard error of measurement.
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the four factors, which emphasises the specificity of
ICAF for fibromyalgia patients. This is especially pro-
nounced both active and passive coping factors. The
control subjects do not have symptoms that interfere
with their lives, namely pain, and thus it clearly makes
no sense to discuss coping strategies.
The differences are still more evident on the physical
scale, in which the mean patient score is four times that
obtained with the controls (see Table 3).
All these data show the instrument’s capacity to differ-
entiate between the two population groups.
Therefore, the ICAF has a set of domains relevant to
fibromyalgia and it largely responds to the need men-
tioned by several authors: to have an extensive set of
measures for the syndrome that can be used in both
clinical trials [3] and in daily clinical practice. The ICAF
was developed and compared to physical functionality
tests, encompassing the domains in which there was the
greatest consensus at OMERACT 9 [3].
This instrument also includes the evaluation of emo-
tional aspects such as depression and anxiety. The latter
is known as a domain of interest for research, as distress
may contribute to increasing the importance of the
painful points characteristic of the ACR classification.
One of the inconveniences of the ICAF may be its
length, given that it includes 59 items, compared to
most of the tools used for FM patients. However, if we
consider that to obtain the same information collected
by the ICAF, several different tools must be used
together, adding up into many more items, we can con-
clude that the ICAF saves a considerable amount of
time for both the doctor and the patient. The average
time that the patient needs to fill the ICAF is 15
minutes.
The ICAF shows well balanced information about the
main areas of severity in FM. Some scales have a small
but clinically significant relevance, such as passive cop-
ing, while the remaining scales, as well as global score,
Table 3 T scores (mean = 50, SD = 10) of fibromyalgia patients and controls
FM patients, N = 232 Control subjects, N = 110
Total Emot. Phys. Actv.C. Pass.C. Total Emot. Phys. Actv.C. Pass.C.
Mean 52.55 50.74 54.27 49.11 51.57 34.31 39.78 12.70 29.41 28.21
Minim. 34.05 37.75 18.93 23.38 24.23 22.44 35.61 4.06 23.38 24.23
Maxim. 78.79 68.28 76.30 68.31 72.91 53.46 54.94 45.76 57.49 62.48
Range 44.73 30.53 57.38 44.93 48.68 31.02 19.33 41.70 34.11 38.25
25th Perc. 46.98 45.86 47.61 41.68 43.00 31.34 36.10 6.30 23.38 24.23
50th 52.27 49.20 55.44 49.17 52.73 33.14 39.10 10.01 24.21 24.23
75th 57.77 54.44 61.40 56.45 59.69 36.03 41.13 16.72 34.40 28.75
Key: Total: general score including all the four factors, Emot.: score for the emotional factor; Phys.: score for the physical factor, Actv.C.: score for the active
coping factor, Pass.C.: score for the passive coping factor.
Figure 1 Graphic representation of mean scores of fibromyalgia patients and controls in the ICAF factors.
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are very useful for understanding the clinical situation of
the patient and for starting up with treatment.
In relation with the length of the ICAF, it is possible
that future studies may reduce the number of items pre-
serving the information offered.
The fact that this study was conducted in Spain may
be a limitation to generalize ICAF to other patients in
different countries. This limitation may affect the ICAF
structure but not the items because they were selected
from well-known instruments validated in most coun-
tries [6].
Conclusions
The findings suggest that the ICAF is a valid, reliable,
sensitive to change instrument with the added advantage
that it offers some additional domains (factors) that pro-
vide very valuable information regarding the most deli-
cate aspects of the patient, which must be addressed at
the time of treatment.
The areas of evaluation of the ICAF also coincide, in
general, with those proposed by Wolfe et al. [2], and
have also been developed with two data sources: those
coming from the patient and those from the medical
examination.
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